Visão geral da empresa
Cingulate Inc. operates as a biopharmaceutical entity focused on developing pharmaceutical products utilizing proprietary drug delivery platform technology specifically for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety within the United States market. The company functions within the broader Healthcare sector, specifically classified under the Biotechnology industry, which typically involves high-risk, high-reward research and development cycles aimed at creating novel therapies with significant potential regulatory and commercial value. Currently, the organization employs a workforce of 14 individuals and maintains a market capitalization of $69.31M, reflecting its status as a small-cap entity within the specialized biotech landscape. The combination of a modest market cap and the absence of reported annual revenue indicates that the company is in an early-stage operational phase where capital is primarily allocated toward product development and clinical trials rather than commercial scale-up or profitability.
Saúde financeira
The financial performance of Cingulate Inc. is characterized by significant losses across the board, with the trailing twelve-month net income recorded at a loss of $22,449,912, while the EBITDA stands at $-19,397,214. The distinction between the revenue metric, which is not available, and the substantial net loss reveals a cost structure dominated by research and development expenses, typical for a biotechnology firm in the pre-revenue stage where operating costs far exceed any current sales generation. Free cash flow for the period is reported at $-10,425,198, indicating that the company is consuming cash reserves to fund its operations and product development efforts, thereby limiting immediate financial flexibility for external expansion or acquisitions. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that signifies the company has not yet achieved commercial revenue to generate meaningful gross profit or operating leverage. On the balance sheet, the company holds $10.95M in cash against $8.79M in debt, resulting in a Debt to Equity ratio of 350.21, which suggests a highly leveraged position relative to shareholder equity, although the absolute debt load is manageable given the cash on hand. Liquidity in the short term is assessed via a Current Ratio of 1.16, indicating that current assets slightly exceed current liabilities, providing a minimal but functional buffer for meeting short-term obligations without immediate distress. Return on Equity stands at -450.6% and Return on Assets at -83.2%, metrics that highlight the intense capital dilution or expense absorption relative to the equity base and asset utilization, pointing to a management strategy focused on growth investment rather than immediate return generation.
Avaliação de valorização
Valuation metrics for Cingulate Inc. present a complex picture typical of unprofitable biotechnology firms, with the Trailing P/E ratio listed as N/A due to the lack of positive earnings, while the Forward P/E is calculated at -4.10, implying a market expectation of continued losses or a specific accounting treatment for future earnings estimates. The Price to Book ratio is elevated at 17.23, suggesting that the market values the company's intangible assets, such as its drug delivery platform technology and intellectual property, at a significant premium over its book value. Alternative valuation measures include a Price to Sales ratio of N/A and an EV/EBITDA of -3.46, figures that reinforce the company's current lack of profitability and suggest that traditional multiple-based comparisons with profitable peers are not applicable. The stock has exhibited volatility over the past year, trading between a 52-Week Low of $3.20 and a 52-Week High of $11.89, a range that defines the current trading environment for this speculative asset. The Beta of -0.77 indicates an inverse correlation to the broader market, meaning the stock tends to move in the opposite direction of the general market index, adding a layer of non-standard volatility risk to the investment profile.
Growth & Income
Growth metrics for Cingulate Inc. are currently unavailable, with Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A, reflecting the company's pre-commercial status where historical year-over-year data is not yet established. Consequently, the company does not function as a dividend payer, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that all available earnings or cash reserves are retained to fund ongoing research, development, and operational expenditures rather than distributed to shareholders. The absence of a dividend policy is standard for biotechnology companies in the development phase, where capital preservation and reinvestment are prioritized over income generation for investors. The overall growth and income profile is defined by a reliance on future product approvals and commercialization potential rather than current earnings growth or dividend yields, creating a speculative investment thesis based entirely on the successful execution of the lead product candidate CTx-1301.